EDIT

Over the past six months, several events have impacted Editas Medicine's stock price. In October 2026, Editas Medicine received regulatory approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in Australia, accompanied by an upgrade from Wells Fargo. In September 2026, the company announced the appointment of Dan Ory, M.D., as its new Chief Medical Officer and participated in investor conferences. In August 2026, Editas Medicine reported a narrower-than-expected net loss of $0.15 per share for its second-quarter 2026 financial results, though shares slipped by 1.95%. The company also presented new preclinical data for EDIT-401 demonstrating significant reductions in LDL-C in non-human primates. In May 2026, Editas Medicine reported its first-quarter 2026 results, continuing to advance EDIT-401 towards clinical trials and expecting early human proof-of-concept data by year-end 2026, while also noting a reaffirmation by the U.S. Patent and Trademark Office in favor of the Broad Institute regarding CRISPR/Cas9 interference. The stock experienced a slight decline of 0.34% over the past six months.